These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35034207)

  • 1. Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.
    Leatherdale A; Stukas S; Lei V; West HE; Campbell CJ; Hoiland RL; Cooper J; Wellington CL; Sekhon MS; Pryzdial ELG; Conway EM
    Med Microbiol Immunol; 2022 Feb; 211(1):37-48. PubMed ID: 35034207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.
    Holter JC; Pischke SE; de Boer E; Lind A; Jenum S; Holten AR; Tonby K; Barratt-Due A; Sokolova M; Schjalm C; Chaban V; Kolderup A; Tran T; Tollefsrud Gjølberg T; Skeie LG; Hesstvedt L; Ormåsen V; Fevang B; Austad C; Müller KE; Fladeby C; Holberg-Petersen M; Halvorsen B; Müller F; Aukrust P; Dudman S; Ueland T; Andersen JT; Lund-Johansen F; Heggelund L; Dyrhol-Riise AM; Mollnes TE
    Proc Natl Acad Sci U S A; 2020 Oct; 117(40):25018-25025. PubMed ID: 32943538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d.
    Kowalska D; Kuźniewska A; Senent Y; Tavira B; Inogés S; López-Díaz de Cerio A; Pio R; Okrój M; Yuste JR
    Front Immunol; 2022; 13():946522. PubMed ID: 36091057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.
    Sinkovits G; Mező B; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Front Immunol; 2021; 12():663187. PubMed ID: 33841446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients.
    Barratt-Due A; Pettersen K; Børresdatter-Dahl T; Holter JC; Grønli RH; Dyrhol-Riise AM; Lerum TV; Holten AR; Tonby K; Trøseid M; Skjønsberg OH; Granerud BK; Heggelund L; Kildal AB; Schjalm C; Aaløkken TM; Aukrust P; Ueland T; Mollnes TE; Halvorsen B;
    J Intern Med; 2024 Jul; 296(1):80-92. PubMed ID: 38539241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality.
    Alosaimi B; Mubarak A; Hamed ME; Almutairi AZ; Alrashed AA; AlJuryyan A; Enani M; Alenzi FQ; Alturaiki W
    Front Immunol; 2021; 12():668725. PubMed ID: 34276659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation predicts negative outcomes in COVID-19: The experience from Northen Italian patients.
    Meroni PL; Croci S; Lonati PA; Pregnolato F; Spaggiari L; Besutti G; Bonacini M; Ferrigno I; Rossi A; Hetland G; Hollan I; Cugno M; Tedesco F; Borghi MO; Salvarani C
    Autoimmun Rev; 2023 Jan; 22(1):103232. PubMed ID: 36414219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of complement pathways with COVID-19 severity and outcomes.
    Devalaraja-Narashimha K; Ehmann PJ; Huang C; Ruan Q; Wipperman MF; Kaplan T; Liu C; Afolayan S; Glass DJ; Mellis S; Yancopoulos GD; Hamilton JD; MacDonnell S; Hamon SC; Boyapati A; Morton L
    Microbes Infect; 2023 May; 25(4):105081. PubMed ID: 36494054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality.
    Defendi F; Leroy C; Epaulard O; Clavarino G; Vilotitch A; Le Marechal M; Jacob MC; Raskovalova T; Pernollet M; Le Gouellec A; Bosson JL; Poignard P; Roustit M; Thielens N; Dumestre-Pérard C; Cesbron JY
    Front Immunol; 2021; 12():742446. PubMed ID: 34567008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study.
    Charitos P; Heijnen IAFM; Egli A; Bassetti S; Trendelenburg M; Osthoff M
    Front Immunol; 2021; 12():765330. PubMed ID: 34777382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.
    Siggins MK; Davies K; Fellows R; Thwaites RS; Baillie JK; Semple MG; Openshaw PJM; Zelek WM; Harris CL; Morgan BP;
    Immunology; 2023 Mar; 168(3):473-492. PubMed ID: 36175370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation and endothelial perturbation parallel COVID-19 severity and activity.
    Cugno M; Meroni PL; Gualtierotti R; Griffini S; Grovetti E; Torri A; Lonati P; Grossi C; Borghi MO; Novembrino C; Boscolo M; Uceda Renteria SC; Valenti L; Lamorte G; Manunta M; Prati D; Pesenti A; Blasi F; Costantino G; Gori A; Bandera A; Tedesco F; Peyvandi F
    J Autoimmun; 2021 Jan; 116():102560. PubMed ID: 33139116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
    Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
    Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection: A prospective cohort study.
    Bruni F; Charitos P; Lampart M; Moser S; Siegemund M; Bingisser R; Osswald S; Bassetti S; Twerenbold R; Trendelenburg M; Rentsch KM; Osthoff M
    Front Immunol; 2022; 13():941742. PubMed ID: 36203596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Distinct Immunophenotypes in Critically Ill Coronavirus Disease 2019 Patients.
    Dupont T; Caillat-Zucman S; Fremeaux-Bacchi V; Morin F; Lengliné E; Darmon M; Peffault de Latour R; Zafrani L; Azoulay E; Dumas G
    Chest; 2021 May; 159(5):1884-1893. PubMed ID: 33316234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce.
    Laudanski K; Okeke T; Siddiq K; Hajj J; Restrepo M; Gullipalli D; Song WC
    Sci Rep; 2022 Aug; 12(1):13658. PubMed ID: 35953544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement Activation in Kidneys of Patients With COVID-19.
    Pfister F; Vonbrunn E; Ries T; Jäck HM; Überla K; Lochnit G; Sheriff A; Herrmann M; Büttner-Herold M; Amann K; Daniel C
    Front Immunol; 2020; 11():594849. PubMed ID: 33584662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the  phase 2 PANAMO trial.
    Lim EHT; Vlaar APJ; Bos LDJ; van Vught LA; Boer AMT; Dujardin RWG; Habel M; Xu Z; Brouwer MC; van de Beek D; de Bruin S;
    Respir Res; 2022 Dec; 23(1):375. PubMed ID: 36566174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins.
    Ali YM; Ferrari M; Lynch NJ; Yaseen S; Dudler T; Gragerov S; Demopulos G; Heeney JL; Schwaeble WJ
    Front Immunol; 2021; 12():714511. PubMed ID: 34290717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.